TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05713253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELITA System
Description: Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
Study: NCT05292664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Taken intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Taken intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Lumbar Puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Taken Orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Taken Orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Taken Orally or intravenously
Study: NCT06162559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib 300mg is taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
Study: NCT05134285

Intervention type: OTHER
Intervention: blood pressure,BMI, blood sample
Description: Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

Intervention type: OTHER
Intervention: blood pressure,BMI, blood sample
Description: Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

Intervention type: OTHER
Intervention: blood pressure,BMI, blood sample
Description: Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
Study: NCT04883294

Intervention type: DIAGNOSTIC_TEST
Intervention: Electronic Nose
Description: All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electronic Nose
Description: All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
Study: NCT04608409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Paclitaxel
Description: Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Paclitaxel
Description: Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Paclitaxel
Description: Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Paclitaxel
Description: Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
Study: NCT05292664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken Orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Taken intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Taken intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Taken intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Taken intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: Given as intramuscular injection
Study: NCT05579951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific instrumentation
Description: Total knee replacement with patient specific instrumentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Total knee replacement with conventional instrumentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific instrumentation
Description: Medacta GMK Sphere MyKnee Patient specific Instrumentation
Study: NCT04931251

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial Navigation
Description: providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
Study: NCT05401578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab
Description: Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% NaCl)
Description: 1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
Study: NCT06343779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant, Placebo
Description: Deucrictibant Soft Capsules for Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant, Placebo
Description: Deucrictibant Soft Capsules for Oral Use
Study: NCT06534060

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Genetic: MB-105
Description: MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
Study: NCT05814653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment-Primary Care
Description: Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Based Treatment
Description: Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
Study: NCT06081452

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
Study: NCT05808257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fibre Laser
Description: The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:Yttrium-Aluminum-Garnet
Description: The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
Study: NCT05627245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Pharmacokinetic study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET-CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT05823220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homeless diversion (HD)
Description: Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
Study: NCT05962398

Intervention type: GENETIC
Intervention: AAV5-hFIXco-Padua
Description: Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).
Study: NCT06391398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stoma care education with the Stoma Care Training Belt
Description: Stoma care education
Study: NCT06016387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib 150 MG
Description: Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain & Spinal Radiation
Description: Brain \& Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
Study: NCT06493227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No routine fibrinolysis inhibitors after surgery
Description: Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine fibrinolysis inhibitors after surgery
Description: During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.
Study: NCT06243744

Intervention type: DEVICE
Group type: OTHER
Intervention: Renuvion APR System
Description: The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
Study: NCT05729802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoloSIM Software via Hololens 2
Description: Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training by Mannequin Based Simulation
Description: Participants will train a via traditional mannequin based medical crisis scenario
Study: NCT05643430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom Ultra
Description: The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
Study: NCT06036602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAD3-Sudan Ebolavirus Vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution for injection.
Study: NCT04960384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-2
Description: The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
Study: NCT06131723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed tickler email
Description: The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
Study: NCT05099679

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy (supportive counseling)
Description: Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Cardiac Rehabilitation
Description: If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
Study: NCT06463587

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Low Dose
Description: Participants will receive cladribine low dose in two courses separated by 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cladribine Low Dose
Description: Participants will receive cladribine low dose in two courses separated by 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine High Dose
Description: Participants will receive a total of cladribine high dose in two courses separated by 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cladribine High Dose
Description: Participants will receive a total of cladribine high dose in two courses separated by 4 weeks.
Study: NCT06548360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study: NCT05266365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The video-based exercise (VBE) group
Description: An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The physiotherapist will create a video record for the patients, including a detailed description of each exercise.~This video recording will be watched at home, and the patients will do video-based exercises by following the instructions in the video.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The standard exercise group (SE)
Description: An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~An exercise program will be performed at the clinic.
Study: NCT05781061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for Eligibility
Description: Asynchronous Screening for MA Eligibility
Study: NCT06044311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: 200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Neoadjuvant chemotherapy treatment as per standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Radiation
Description: Neoadjuvant radiation treatment as per standard of care.